Credit Suisse’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Credit Suisse’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-41,109	Closed	-$1.08M	–	4210
2015 Q3	$1.08M	Buy	41,109 +26,992	+191%	+$913K	﹤0.01%	2752
2015 Q2	$511K	Sell	14,117 -155	-1%	-$5.33K	﹤0.01%	3708
2015 Q1	$469K	Buy	+14,272	New	+$436K	﹤0.01%	3585

Other funds holding BBC

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Liberty Street Advisors New York $507M AUM 59.45% 1-Year Est. Return

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Credit Suisse's BBC Position: Q4 2015 in Review

Credit Suisse sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q4 2015, closing a stake of 41,109 shares — an estimated $1.08M sold.

Credit Suisse first reported a position in BBC in Q1 2015 and held it in 3 quarters. The position peaked at $1.08M in Q3 2015. 17 funds tracked by Wall St. Rank hold BBC as of Q4 2015.

Credit Suisse reported no remaining Virtus Biotech Clinical Trials ETF position as of Q4 2015 after selling out during the quarter.
Credit Suisse sold 41,109 Virtus Biotech Clinical Trials ETF shares in Q4 2015, an estimated $1.08M.
Credit Suisse first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2015 and held it in 3 quarters.
Credit Suisse's Virtus Biotech Clinical Trials ETF position peaked at $1.08M in Q3 2015.
17 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2015.

Based on Credit Suisse's 13F filing for Q4 2015, filed 16 Feb 2016.